Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.004 USD | +1.51% | +0.93% | +0.06% |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
03-29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.06% | 19.43M | |
+29.43% | 684B | |
+30.05% | 568B | |
-4.04% | 361B | |
+18.42% | 329B | |
+4.88% | 284B | |
+15.98% | 240B | |
+9.52% | 208B | |
-6.83% | 200B | |
+8.05% | 166B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating